Guangxi Wuzhou Zhongheng Group Co Ltd (600252) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Guangxi Wuzhou Zhongheng Group Co Ltd (600252) has a cash flow conversion efficiency ratio of -0.011x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥-76.63 Million ≈ $-11.21 Million USD) by net assets (CN¥7.26 Billion ≈ $1.06 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of Guangxi Wuzhou Zhongheng Group Co Ltd to measure how many days the company can operate on defensive assets alone.
Guangxi Wuzhou Zhongheng Group Co Ltd - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Guangxi Wuzhou Zhongheng Group Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Guangxi Wuzhou Zhongheng Group Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Guangxi Wuzhou Zhongheng Group Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zhejiang Dehong Automotive
SHG:603701
|
-0.014x |
|
Montnets Cloud Technology Group Co Ltd
SHE:002123
|
0.032x |
|
Cybrid Technologies Inc
SHG:603212
|
0.041x |
|
Tianjin Benefo Tejing Electric Co Ltd
SHG:600468
|
0.001x |
|
Taiwan Semiconductor Co Ltd
TWO:5425
|
0.054x |
|
MA Financial Group Ltd
AU:MAF
|
0.847x |
|
Inwido AB
ST:INWI
|
-0.029x |
|
Akasha Wira International Tbk
JK:ADES
|
0.056x |
Annual Cash Flow Conversion Efficiency for Guangxi Wuzhou Zhongheng Group Co Ltd (1999–2025)
The table below shows the annual cash flow conversion efficiency of Guangxi Wuzhou Zhongheng Group Co Ltd from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Guangxi Wuzhou Zhongheng Group Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | CN¥6.74 Billion ≈ $986.86 Million |
CN¥-18.91 Million ≈ $-2.77 Million |
-0.003x | -104.41% |
| 2024-12-31 | CN¥7.51 Billion ≈ $1.10 Billion |
CN¥477.43 Million ≈ $69.86 Million |
0.064x | +8.62% |
| 2023-12-31 | CN¥8.28 Billion ≈ $1.21 Billion |
CN¥484.10 Million ≈ $70.84 Million |
0.058x | +385.05% |
| 2022-12-31 | CN¥8.29 Billion ≈ $1.21 Billion |
CN¥-170.09 Million ≈ $-24.89 Million |
-0.021x | -132.36% |
| 2021-12-31 | CN¥8.69 Billion ≈ $1.27 Billion |
CN¥-76.74 Million ≈ $-11.23 Million |
-0.009x | -111.07% |
| 2020-12-31 | CN¥8.23 Billion ≈ $1.20 Billion |
CN¥656.62 Million ≈ $96.08 Million |
0.080x | -21.97% |
| 2019-12-31 | CN¥6.40 Billion ≈ $936.15 Million |
CN¥654.31 Million ≈ $95.75 Million |
0.102x | -28.93% |
| 2018-12-31 | CN¥5.93 Billion ≈ $867.77 Million |
CN¥853.40 Million ≈ $124.88 Million |
0.144x | -9.83% |
| 2017-12-31 | CN¥5.60 Billion ≈ $818.98 Million |
CN¥893.21 Million ≈ $130.71 Million |
0.160x | -43.17% |
| 2016-12-31 | CN¥5.33 Billion ≈ $779.28 Million |
CN¥1.50 Billion ≈ $218.86 Million |
0.281x | +377.32% |
| 2015-12-31 | CN¥4.95 Billion ≈ $725.03 Million |
CN¥291.53 Million ≈ $42.66 Million |
0.059x | -38.91% |
| 2014-12-31 | CN¥5.92 Billion ≈ $865.96 Million |
CN¥569.95 Million ≈ $83.40 Million |
0.096x | -62.41% |
| 2013-12-31 | CN¥3.69 Billion ≈ $539.83 Million |
CN¥945.10 Million ≈ $138.30 Million |
0.256x | -12.24% |
| 2012-12-31 | CN¥3.11 Billion ≈ $454.39 Million |
CN¥906.43 Million ≈ $132.64 Million |
0.292x | +255.33% |
| 2011-12-31 | CN¥2.00 Billion ≈ $292.73 Million |
CN¥-375.93 Million ≈ $-55.01 Million |
-0.188x | -231.00% |
| 2010-12-31 | CN¥1.34 Billion ≈ $195.58 Million |
CN¥191.73 Million ≈ $28.06 Million |
0.143x | +394.70% |
| 2009-12-31 | CN¥576.93 Million ≈ $84.42 Million |
CN¥-28.08 Million ≈ $-4.11 Million |
-0.049x | -137.00% |
| 2008-12-31 | CN¥451.95 Million ≈ $66.13 Million |
CN¥59.47 Million ≈ $8.70 Million |
0.132x | +33.92% |
| 2007-12-31 | CN¥414.81 Million ≈ $60.70 Million |
CN¥40.75 Million ≈ $5.96 Million |
0.098x | -82.41% |
| 2006-12-31 | CN¥356.94 Million ≈ $52.23 Million |
CN¥199.41 Million ≈ $29.18 Million |
0.559x | +283.23% |
| 2005-12-31 | CN¥385.08 Million ≈ $56.35 Million |
CN¥56.14 Million ≈ $8.21 Million |
0.146x | -51.80% |
| 2004-12-31 | CN¥476.29 Million ≈ $69.70 Million |
CN¥144.06 Million ≈ $21.08 Million |
0.302x | +207.96% |
| 2003-12-31 | CN¥438.88 Million ≈ $64.22 Million |
CN¥-122.95 Million ≈ $-17.99 Million |
-0.280x | -77.66% |
| 2002-12-31 | CN¥428.29 Million ≈ $62.67 Million |
CN¥-67.54 Million ≈ $-9.88 Million |
-0.158x | -436.43% |
| 2001-12-31 | CN¥399.28 Million ≈ $58.43 Million |
CN¥-11.74 Million ≈ $-1.72 Million |
-0.029x | +36.69% |
| 2000-12-31 | CN¥375.55 Million ≈ $54.95 Million |
CN¥-17.44 Million ≈ $-2.55 Million |
-0.046x | -113.21% |
| 1999-12-31 | CN¥148.77 Million ≈ $21.77 Million |
CN¥52.29 Million ≈ $7.65 Million |
0.351x | -- |
About Guangxi Wuzhou Zhongheng Group Co Ltd
Guangxi Wuzhou Zhongheng Group Co., Ltd, together with its subsidiaries, researches, develops, manufactures, and sells pharmaceuticals in China. The company offers traditional Chinese medicine, including Xueshuantong injection, Zhonghua Dieda Wan for traumatic injuries, Fuyanjing capsules, JieShiTong tablets, snake gall and fritillaria liquid, Kunyuean granules, and compound clam oral liquid for … Read more